title: A simplified approach for the molecular classification of glioblastomas.
abstract: Glioblastoma (GBM) is the most common malignant primary brain tumors in adults and exhibit striking aggressiveness. Although GBM constitute a single histological entity, they exhibit considerable variability in biological behavior, resulting in significant differences in terms of prognosis and response to treatment. In an attempt to better understand the biology of GBM, many groups have performed high-scale profiling studies based on gene or protein expression. These studies have revealed the existence of several GBM subtypes. Although there remains to be a clear consensus, two to four major subtypes have been identified. Interestingly, these different subtypes are associated with both differential prognoses and responses to therapy. In the present study, we investigated an alternative immunohistochemistry (IHC)-based approach to achieve a molecular classification for GBM. For this purpose, a cohort of 100 surgical GBM samples was retrospectively evaluated by immunohistochemical analysis of EGFR, PDGFRA and p53. The quantitative analysis of these immunostainings allowed us to identify the following two GBM subtypes: the "Classical-like" (CL) subtype, characterized by EGFR-positive and p53- and PDGFRA-negative staining and the "Proneural-like" (PNL) subtype, characterized by p53- and/or PDGFRA-positive staining. This classification represents an independent prognostic factor in terms of overall survival compared to age, extent of resection and adjuvant treatment, with a significantly longer survival associated with the PNL subtype. Moreover, these two GBM subtypes exhibited different responses to chemotherapy. The addition of temozolomide to conventional radiotherapy significantly improved the survival of patients belonging to the CL subtype, but it did not affect the survival of patients belonging to the PNL subtype. We have thus shown that it is possible to differentiate between different clinically relevant subtypes of GBM by using IHC-based profiling, a method that is advantageous in its ease of daily implementation and in large-scale clinical application.
authors.affiliation: Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
authors.forename: Marie
authors.initials: M
authors.lastname: Le Mercier
authors.forename: Delfyne
authors.initials: D
authors.lastname: Hastir
authors.forename: Xavier
authors.initials: X
authors.lastname: Moles Lopez
authors.forename: Nancy
authors.initials: N
authors.lastname: De Nève
authors.forename: Calliope
authors.initials: C
authors.lastname: Maris
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Trepant
authors.forename: Sandrine
authors.initials: S
authors.lastname: Rorive
authors.forename: Christine
authors.initials: C
authors.lastname: Decaestecker
authors.forename: Isabelle
authors.initials: I
authors.lastname: Salmon
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D001932:Brain Neoplasms / Q000145:classification* / Q000378:metabolism* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D005909:Glioblastoma / Q000145:classification* / Q000378:metabolism* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D055815:Young Adult
chemical_list: D016159:Tumor Suppressor Protein p53; D066246:ErbB Receptors; D020796:Receptor, Platelet-Derived Growth Factor alpha